What is LOPJLB’s current signal on LTRN?

LOPJLB’s latest quantitative signal on Lantern Pharma Inc. (LTRN) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is LTRN in?

Lantern Pharma Inc. (LTRN) is currently classified in the CRISIS HMM market regime on LOPJLB.

What does Lantern Pharma Inc. (LTRN) do?

Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also adv…

Lantern Pharma Inc. (LTRN)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$0.71-4.05%Close

SELLCRISIS · day 44

Company news

gurufocus.com · 8d ago

Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC

businesswire.com · 8d ago

Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC

businesswire.com · 14d ago

Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering

businesswire.com · 16d ago

Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering

seekingalpha.com · 21d ago

Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development Transcript

gurufocus.com · 22d ago

Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET

businesswire.com · 22d ago

Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET

businesswire.com · 23d ago

Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas

businesswire.com · 28d ago

Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23

seekingalpha.com · 61d ago

Lantern Pharma Inc. (LTRN) Q2 2026 Earnings Call Transcript

businesswire.com · 62d ago

Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

gurufocus.com · 69d ago

Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET

businesswire.com · 69d ago

Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET

gurufocus.com · 73d ago

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine

businesswire.com · 73d ago

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine

businesswire.com · 79d ago

Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer

businesswire.com · 84d ago

Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers

Market news & ticker search · RSS for LTRN

FAQ

What is LOPJLB’s current signal on LTRN?: LOPJLB’s latest quantitative signal on Lantern Pharma Inc. (LTRN) is SELL in a CRISIS regime. Signals are updated daily.
What market regime is LTRN in?: Lantern Pharma Inc. (LTRN) is currently classified in the CRISIS HMM market regime on LOPJLB.
What does Lantern Pharma Inc. (LTRN) do?: Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also adv…

Lantern Pharma Inc. (LTRN)

Key stats

Prediction markets

Company news

FAQ